Stereotaxis will announce its 2025 financial results on March 9, 2026, with a conference call at 4:30 p.m. ET.
Quiver AI Summary
Stereotaxis, a leader in surgical robotics for minimally invasive endovascular procedures, announced that it will disclose its financial results for the fourth quarter and full year of 2025 on March 9, 2026, following the close of U.S. financial markets. A conference call and webcast will be held at 4:30 p.m. ET to discuss the results and corporate developments. Interested parties can access the call via phone or through the company's investor relations website. Stereotaxis focuses on advancing robotic systems and solutions for interventional laboratories, aiming to improve patient care and enhance operational efficiency. The company has treated over 150,000 patients globally.
Potential Positives
- Stereotaxis is scheduled to release its financial results for the fourth quarter and full year of 2025, indicating a commitment to transparency and communication with stakeholders.
- The upcoming conference call and webcast reflect the company's proactive approach in engaging with investors regarding its financial performance and corporate developments.
- Stereotaxis highlights its leadership in surgical robotics for minimally invasive interventions, showcasing the significance of its technological advancements in improving patient care.
- The company has treated over 150,000 patients globally, which demonstrates its established presence and effectiveness in the medical technology market.
Potential Negatives
- The press release does not provide any financial performance expectations or forecasts ahead of the results announcement, which may raise concerns among investors about potential underwhelming performance.
- There is no mention of any key achievements or milestones reached during 2025, which could lead to skepticism about the company's growth and innovation during that period.
- The timing of the announcement may suggest that the company is waiting until the last minute to disclose results, potentially indicating a lack of confidence in their financial outcomes.
FAQ
When will Stereotaxis release its 2025 financial results?
Stereotaxis will release its financial results on Monday, March 9, 2026, at the close of the U.S. markets.
What time is the Stereotaxis conference call?
The conference call is scheduled for 4:30 p.m. ET on March 9, 2026.
How can I access the Stereotaxis conference call?
You can dial 800-715-9871 (US and Canada) or 646-307-1963 (International) with pass code 8365695.
Where can I find the webcast for the conference call?
The webcast will be available in the investor relations section of Stereotaxis’ website at http://ir.stereotaxis.com/.
Will there be a replay of the conference call?
Yes, a phone replay will be available for one month starting about four hours after the call ends.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$STXS Insider Trading Activity
$STXS insiders have traded $STXS stock on the open market 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $STXS stock by insiders over the last 6 months:
- PAUL J ISAAC has made 2 purchases buying 30,000 shares for an estimated $66,600 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$STXS Revenue
$STXS had revenues of $7.5M in Q3 2025. This is a decrease of -18.83% from the same period in the prior year.
You can track STXS financials on Quiver Quantitative's STXS stock page.
$STXS Hedge Fund Activity
We have seen 56 institutional investors add shares of $STXS stock to their portfolio, and 31 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- STATE OF WYOMING removed 392,567 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $1,220,883
- TWO SIGMA INVESTMENTS, LP added 361,888 shares (+inf%) to their portfolio in Q3 2025, for an estimated $1,125,471
- RENAISSANCE TECHNOLOGIES LLC added 336,600 shares (+768.5%) to their portfolio in Q3 2025, for an estimated $1,046,826
- VANGUARD GROUP INC added 251,663 shares (+7.3%) to their portfolio in Q4 2025, for an estimated $578,824
- TWO SIGMA ADVISERS, LP added 171,600 shares (+inf%) to their portfolio in Q3 2025, for an estimated $533,676
- WARBERG ASSET MANAGEMENT LLC removed 151,633 shares (-12.6%) from their portfolio in Q3 2025, for an estimated $471,578
- UBS GROUP AG added 141,721 shares (+168.9%) to their portfolio in Q4 2025, for an estimated $325,958
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$STXS Analyst Ratings
Wall Street analysts have issued reports on $STXS in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Citizens issued a "Market Outperform" rating on 12/16/2025
To track analyst ratings and price targets for $STXS, check out Quiver Quantitative's $STXS forecast page.
$STXS Price Targets
Multiple analysts have issued price targets for $STXS recently. We have seen 2 analysts offer price targets for $STXS in the last 6 months, with a median target of $4.0.
Here are some recent targets:
- Daniel Stauder from Citizens set a target price of $4.0 on 12/16/2025
- Kyle Bauser from Roth Capital set a target price of $4.0 on 11/12/2025
Full Release
ST. LOUIS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2025 fourth quarter and full year on Monday, March 9, 2026 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. ET that day to discuss the Company’s results and corporate developments.
| What: | Stereotaxis fourth quarter and full year 2025 financial results conference call |
| When: | Monday, March 9, 2026, at 4:30 p.m. ET (1:30 p.m. PT) |
| Dial In Number: | To access the live call, dial 800-715-9871 (US and Canada) or 646-307-1963 (International) and give the participant pass code 8365695. |
| Webcast: | To access the live and replay webcast, please visit the investor relations section of Stereotaxis’ website at http://ir.stereotaxis.com/ . |
| Call Replay: | A phone replay of the call will be available for one month beginning approximately four hours following the end of the call. To request access for a replay of the conference call, please click here . |
About Stereotaxis
Stereotaxis
(NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit
www.stereotaxis.com
.
Investor Contacts:
David L. Fischel
Chairman and Chief Executive Officer
Kimberly Peery
Chief Financial Officer
314-678-6100
[email protected]
